Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations (?MMPR?). The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in in Toronto, Canada.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorFinance
SymbolNASDAQ:CRON
CUSIPN/A
Phone212-590-9070
Debt
Debt-to-Equity Ratio0.02
Current Ratio52.98
Quick Ratio44.71
Price-To-Earnings
Trailing P/E Ratio1,072.00
Forward P/E Ratio-1,072.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.15 million
Price / Sales602.97
Cash Flow$0.0181 per share
Price / Cash591.68
Book Value$0.47 per share
Price / Book22.81
Profitability
EPS (Most Recent Fiscal Year)$0.01
Net Income$1.92 million
Net Margins30.64%
Return on Equity2.23%
Return on Assets2.05%
Miscellaneous
Employees103
Outstanding Shares177,180,000
Market Cap$1.97 billion
Cronos Group (NASDAQ:CRON) Frequently Asked Questions
What is Cronos Group's stock symbol?
Cronos Group trades on the NASDAQ under the ticker symbol "CRON."
When is Cronos Group's next earnings date?
What price target have analysts set for CRON?
4 Wall Street analysts have issued 1-year price targets for Cronos Group's stock. Their forecasts range from $4.50 to $4.50. On average, they anticipate Cronos Group's share price to reach $4.50 in the next year. This suggests that the stock has a possible downside of 58.0%. View Analyst Price Targets for Cronos Group.
What is the consensus analysts' recommendation for Cronos Group?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cronos Group.
Who are some of Cronos Group's key competitors?
Some companies that are related to Cronos Group include STADA Arzneimittel (STDAF), USANA Health Sciences (USNA), Foamix Pharmaceuticals (FOMX), Chromadex (CDXC), Mediwound (MDWD), Natural Alternatives International (NAII), Pharmacyte Biotech (PMCB), Mannatech (MTEX), China Jo-Jo Drugstores (CJJD), GLG Life Tech (GLGLF), Cyanotech (CYAN), ImmuDyne (IMMD), Conversion Labs (CVLB), FitLife Brands (FTLF) and True Drinks (TRUU).
Who are Cronos Group's key executives?
Cronos Group's management team includes the folowing people:
- Mr. Michael Gorenstein, Chairman, Pres & CEO (Age 31)
- Mr. William Hilson, Chief Financial Officer
- Mr. David Hsu, Chief Operating Officer
- Ms. Xiuming Shum, Gen. Counsel & Corp. Sec.
- Mr. Jeffrey Jacobson, VP of Bus. Devel.
Who are Cronos Group's major shareholders?
Cronos Group's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Essex Investment Management Co. LLC (0.08%), USA Mutuals Advisors Inc. (0.03%), Lourd Capital LLC (0.02%) and CenterStar Asset Management LLC (0.01%).
Which major investors are selling Cronos Group stock?
CRON stock was sold by a variety of institutional investors in the last quarter, including Lourd Capital LLC.
Which major investors are buying Cronos Group stock?
CRON stock was purchased by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, USA Mutuals Advisors Inc. and CenterStar Asset Management LLC.
How do I buy shares of Cronos Group?
Shares of CRON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cronos Group's stock price today?
One share of CRON stock can currently be purchased for approximately $10.72.
How big of a company is Cronos Group?
Cronos Group has a market capitalization of $1.97 billion and generates $3.15 million in revenue each year. The company earns $1.92 million in net income (profit) each year or $0.01 on an earnings per share basis. Cronos Group employs 103 workers across the globe.
What is Cronos Group's official website?
How can I contact Cronos Group?
Cronos Group's mailing address is 720 KING STREET W SUITE 320, TORONTO A6, M5V 2T3. The company can be reached via phone at 212-590-9070.
MarketBeat Community Rating for Cronos Group (NASDAQ CRON)
MarketBeat's community ratings are surveys of what our community members think about Cronos Group and other stocks. Vote "Outperform" if you believe CRON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRON will underperform the S&P 500 over the long term. You may vote once every thirty days.
